20 results
Granulomatosis with Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021
Polyangiitis (MPA) - ANCA ... Management Algorithm - ACR ... /VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #algorithm #rheumatology
Autoantibodies in Rheumatology
 • Lupus (SLE): ANA (anti-nuclear antibody), dsDNA (double-stranded DNA), Anti-Smith, Anti-Ro (SSA) and
Autoantibodies in Rheumatology ... • Lupus (SLE): ... Anti-cardiolipin (aCl ... Vasculitis: P-ANCA ... Autoantibodies #Rheumatology
Eosinophilic Granulomatosis with Polyangiitis (EGPA) - ANCA Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Active
Polyangiitis (EGPA) - ANCA ... Management Algorithm - ACR ... /VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #algorithm #rheumatology
Rheumatoid Arthritis - ACR 2021 Guidelines
 - Low Disease Activity
 - Moderate to High Disease Activity
Rheumatoid Arthritis - ACR ... 2021 Guidelines ... Tapering DMARDs - Treatment ... #management #treatment ... #rheumatology
Vasculitis Management - ACR/VF 2021 Guidelines for Treatment & Management
 • Giant Cell Arteritis (GCA)
 •
Vasculitis Management - ACR ... /VF 2021 Guidelines ... for Treatment & ... #ACR2021 #Guidelines ... #algorithm #rheumatology
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
thiazidic, PPI, ACE ... constitutional symptoms • Treatment ... life-threatening • Treatment ... management of SLE ... comparison #table #rheumatology
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Erythematosus (SLE ... Workup: - ANA ... 50-60% - pANCA ... life-threatening • Treatment ... Management #Summary #rheumatology
Polyarteritis Nodosa (PAN) - Vasculitis Management Algorithm - ACR/VF 2021 Guidelines
 • Severe Disease → Remission
Management Algorithm - ACR ... /VF 2021 Guidelines ... Vasculitis #Management #Treatment ... #ACR2021 #Guidelines ... #algorithm #rheumatology
2019 EULAR recommendations for thrombosis in (Antiphospholipid Syndrome) APS
Venous Thrombosis - Arterial Thrombosis
INR Target
Duration
Recurrence

Dr. Laurent ARNAUD
Antiphospholipid Syndrome) APS ... Antiphospholipid #Syndrome #APS ... management #EULAR2019 #guidelines ... #rheumatology # ... hematology #treatment
Systemic Lupus Erythematosus - Summary
Antinuclear (ANA) - 95% - Initial screening test
Anti-dsDNA - 50%
 • Associated
Antinuclear (ANA ... • Specific for SLE ... severe disease Treatment ... Erythematosus #SLE ... Summary #diagnosis #rheumatology